GlassScriptPhysician profile
David J Seitz
NPI 1235169194
$11,374.95
in general payments reported to CMS, 2019-2025
32 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,627 · 2022: $1,840 · 2023: $2,564 · 2024: $2,770 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,050 · Education: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,049.82 |
| Education | $857.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,537.78 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,522.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $968.62 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $962.39 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $825.39 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $742.38 | 2021-2025 | Winlevi, Ilumya |
| Amgen INC. | $621.97 | 2021-2025 | Otezla, Otezla, Evenity |
| E.R. Squibb & Sons, L.L.C. | $596.91 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $505.28 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $501.13 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $493.25 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $491.20 | 2021-2025 | |
| Incyte Corporation | $421.89 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $170.06 | 2022-2025 | Cabtreo, Jublia, Siliq |
| Galderma Laboratories, L.P. | $154.03 | 2021-2025 | Nemluvio, Aklief, Oracea |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $120.98 | 2023-2024 | Vtama |
| Biohaven Pharmaceutical Holding Company LTD. | $112.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.96 | 2022-2024 | Spevigo, Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $76.38 | 2021-2025 | Valchlor |
| Janssen Scientific Affairs, LLC | $65.20 | 2021 | |
| Arcutis Biotherapeutics, INC. | $65.01 | 2023-2024 | Zoryve |
| Mylan Institutional INC. | $50.35 | 2023 | Hulio |
| Almirall LLC | $38.79 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $37.25 | 2021 | |
| Convatec INC. | $34.18 | 2025 | |
| Epi Health, LLC | $31.74 | 2021-2022 | |
| Journey Medical Corporation | $31.09 | 2025 | |
| Organon LLC | $29.31 | 2025 | Vtama |
| Biocon Biologics INC | $24.09 | 2023 | Hulio |
| Dermira, INC. | $21.76 | 2021 | |
| Kyowa Kirin, INC. | $17.62 | 2022 | |
| Genentech USA, INC. | $13.65 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Seitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.